Nazli Okumus
Articles
-
Nov 27, 2024 |
radcliffecardiology.com | Sanjiv Shah |Ashley Park |Andrew Coats |Nazli Okumus
Video Published: Views: 22 Likes: 0 Average (ratings) AHA Conference 2024 - Primary safety and efficacy results from ENDEAVOR investigating the effect of myeloperoxidase inhibition with mitiperstat (AstraZeneca) on symptoms and exercise capacity in patients with heart failure with preserved or mildly reduced ejection fraction (HFpEF/HFmrEF).
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →